COMPANY

GlycoMira

HQ: Salt Lake City, UT source · glycomira.com ↗ · Mountain

Keywords: oncology cancer

Location: Salt Lake City, UT · source · Oct 15, 2026

Profile checked Oct 10, 2026

22NIH grants

NIH awards 22

Annual award amounts. Total $11.5M.

Aug 7, 2024 NIH award 5R41AI179525-02 FY2024: $290,351 awarded for that fiscal year; activity R41 (STTR); PI PULSIPHER, ABIGAIL; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Development of a Diagnostic Test for Eosi source ↗
Aug 31, 2023 NIH award 1R41AI179525-01 FY2023: $304,921 awarded for that fiscal year; activity R41 (STTR); PI PULSIPHER, ABIGAIL; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Development of a Diagnostic Test for Eosi source ↗
Jul 31, 2023 NIH award 5SB1DE024024-06 FY2023: $200,442 awarded for that fiscal year; activity SB1 (SBIR); PI SAVAGE, JUSTIN RODNEY; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Glycosaminoglycans to Treat and Preven source ↗
Aug 1, 2022 NIH award 5SB1DE024024-05 FY2022: $1,094,718 awarded for that fiscal year; activity SB1 (SBIR); PI SAVAGE, JUSTIN RODNEY; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Glycosaminoglycans to Treat and Prev source ↗
May 17, 2022 NIH award 5R44AI126987-06 FY2022: $976,018 awarded for that fiscal year; activity R44 (SBIR); PI SAVAGE, JUSTIN RODNEY; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. A Novel Glycosaminoglycan-Based Therap source ↗
Sep 20, 2021 NIH award 2SB1DE024024-04 FY2021: $1,530,893 awarded for that fiscal year; activity SB1 (SBIR); PI LEE, WON YONG YONG; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Glycosaminoglycans to Treat and Prevent source ↗
Jun 24, 2021 NIH award 2R44AI126987-05A1 FY2021: $999,953 awarded for that fiscal year; activity R44 (SBIR); PI PULSIPHER, ABIGAIL; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. A Novel Glycosaminoglycan-Based Therape source ↗
Jan 30, 2020 NIH award 5R44AI126987-04 FY2020: $783,698 awarded for that fiscal year; activity R44 (SBIR); PI PULSIPHER, ABIGAIL; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. A Novel Glycosaminoglycan-Based Therapeut source ↗
Jan 28, 2019 NIH award 5R44AI126987-03 FY2019: $841,614 awarded for that fiscal year; activity R44 (SBIR); PI PULSIPHER, ABIGAIL; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. A Novel Glycosaminoglycan-Based Therapeut source ↗
Feb 5, 2018 NIH award 2R44AI126987-02 FY2018: $781,547 awarded for that fiscal year; activity R44 (SBIR); PI PULSIPHER, ABIGAIL; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. A Novel Glycosaminoglycan-Based Therapeut source ↗
Aug 18, 2017 NIH award 5R44DE024024-03 FY2017: $381,446 awarded for that fiscal year; activity R44 (SBIR); PI LEE, WON YONG YONG; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Glycosaminoglycans to Treat and Prevent R source ↗
Aug 16, 2016 NIH award 2R44DE024024-02A1 FY2016: $364,866 awarded for that fiscal year; activity R44 (SBIR); PI LEE, WON YONG YONG; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Glycosaminoglycans to Treat and Prevent source ↗
Jul 28, 2016 NIH award 1R43AI126987-01 FY2016: $297,614 awarded for that fiscal year; activity R43 (SBIR); PI PULSIPHER, ABIGAIL; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. A Novel Glycosaminoglycan-Based Therapeut source ↗
Apr 27, 2015 NIH award 3R44DE022216-03S1 FY2015: $7,000 awarded for that fiscal year; activity R44 (SBIR); PI SAVAGE, JUSTIN RODNEY; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Anti-Inflammatory Glycosaminoglycan Et source ↗
Jun 23, 2014 NIH award 5R44DE022216-03 FY2014: $685,157 awarded for that fiscal year; activity R44 (SBIR); PI SAVAGE, JUSTIN RODNEY; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Anti-Inflammatory Glycosaminoglycan Et source ↗
Jun 14, 2014 NIH award 1R43DE024024-01 FY2014: $199,997 awarded for that fiscal year; activity R43 (SBIR); PI LEE, WON YONG YONG; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Glycosaminoglycans to Treat and Prevent R source ↗
Sep 19, 2013 NIH award 2R44DE022216-02 FY2013: $814,843 awarded for that fiscal year; activity R44 (SBIR); PI SAVAGE, JUSTIN RODNEY; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Anti-Inflammatory Glycosaminoglycan Et source ↗
Sep 23, 2011 NIH award 1R43CA153452-01A1 FY2011: $210,000 awarded for that fiscal year; activity R43 (SBIR); PI SAVAGE, JUSTIN RODNEY; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Novel Glycosaminoglycan Ethers for P source ↗
Sep 15, 2011 NIH award 1R43DK093413-01 FY2011: $200,024 awarded for that fiscal year; activity R43 (SBIR); PI SAVAGE, JUSTIN RODNEY; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Novel Glycosaminoglycan Derivatives fo source ↗
Jul 29, 2011 NIH award 1R43DE022216-01 FY2011: $210,000 awarded for that fiscal year; activity R43 (SBIR); PI SAVAGE, JUSTIN RODNEY; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Anti-Inflammatory Glycosaminoglycan Et source ↗
Sep 14, 2009 NIH award 1R43EY019786-01 FY2009: $140,000 awarded for that fiscal year; activity R43 (SBIR); PI ZHANG, JIANXING; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Sulfated Polysaccharide Derivatives for Trea source ↗
Apr 24, 2009 NIH award 1R43AR057281-01 FY2009: $149,800 awarded for that fiscal year; activity R43 (SBIR); PI RAO, NARAYANAM VENKATESWARA; recipient as written: GLYCOMIRA, LLC, SALT LAKE CITY, UT. Sulfated Polysaccharide Derivati source ↗